These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 25745013

  • 1. Cediranib aims for a comeback.
    Schmidt C.
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25745013
    [No Abstract] [Full Text] [Related]

  • 2. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
    Ivy SP, Liu JF, Lee JM, Matulonis UA, Kohn EC.
    Expert Opin Investig Drugs; 2016 Mar; 25(5):597-611. PubMed ID: 26899229
    [Abstract] [Full Text] [Related]

  • 3. Drug combo may be effective in ovarian cancer.
    Cancer Discov; 2014 Aug; 4(8):OF8. PubMed ID: 25092763
    [No Abstract] [Full Text] [Related]

  • 4. New agents and new formulations for the treatment of ovarian cancer.
    Sabbatini P.
    Clin Adv Hematol Oncol; 2005 Nov; 3(11):840-2. PubMed ID: 16491624
    [No Abstract] [Full Text] [Related]

  • 5. Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.
    Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimberidou AM, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W, George GC, Camacho LH, Percy Ivy S, Kurzrock R.
    Cancer; 2014 Jul 15; 120(14):2164-73. PubMed ID: 24752867
    [Abstract] [Full Text] [Related]

  • 6. Myelodysplastic Syndrome After Olaparib Treatment in Heavily Pretreated Ovarian Carcinoma.
    Sari M, Saip P.
    Am J Ther; 2019 Jul 15; 26(5):e632-e633. PubMed ID: 30212381
    [No Abstract] [Full Text] [Related]

  • 7. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M.
    Lancet Oncol; 2015 Jan 15; 16(1):87-97. PubMed ID: 25481791
    [Abstract] [Full Text] [Related]

  • 8. Combining targeted therapies in ovarian cancer.
    Scambia G, Salutari V, Ferrandina G.
    Lancet Oncol; 2014 Oct 15; 15(11):1179-81. PubMed ID: 25218905
    [No Abstract] [Full Text] [Related]

  • 9. Clinical implications for cediranib in advanced cervical cancer.
    Tewari KS.
    Lancet Oncol; 2015 Nov 15; 16(15):1447-1448. PubMed ID: 26474520
    [No Abstract] [Full Text] [Related]

  • 10. The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials.
    Vitfell-Pedersen J, Yap TA, Moreno V, Baird RD, Khan AZ, Barton DP, Kaye SB.
    Eur J Gynaecol Oncol; 2012 Nov 15; 33(2):211-3. PubMed ID: 22611966
    [Abstract] [Full Text] [Related]

  • 11. Clinical trials referral resource. Epidermal growth factor receptor inhibitors in clinical trials.
    Dancey JE, Schoenfeldt M.
    Oncology (Williston Park); 2001 Jun 15; 15(6):748-50, 756-8. PubMed ID: 11430207
    [No Abstract] [Full Text] [Related]

  • 12. The role of Cediranib in ovarian cancer.
    Orbegoso C, Marquina G, George A, Banerjee S.
    Expert Opin Pharmacother; 2017 Oct 15; 18(15):1637-1648. PubMed ID: 28933580
    [Abstract] [Full Text] [Related]

  • 13. PARP inhibitors in BRCA mutation-associated ovarian cancer.
    Clamp A, Jayson G.
    Lancet Oncol; 2015 Jan 15; 16(1):10-2. PubMed ID: 25481790
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Olaparib (Lynparza) for advanced ovarian cancer.
    Med Lett Drugs Ther; 2016 Feb 29; 58(1489):e32-3. PubMed ID: 26938702
    [No Abstract] [Full Text] [Related]

  • 16. New drugs for ovarian cancer.
    Kaye SB.
    Clin Adv Hematol Oncol; 2008 Feb 29; 6(2):91-3. PubMed ID: 18347558
    [No Abstract] [Full Text] [Related]

  • 17. The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer.
    Gubbi A, Kendrick JE, Finkler NJ.
    Expert Rev Anticancer Ther; 2014 Oct 29; 14(10):1105-13. PubMed ID: 25189201
    [Abstract] [Full Text] [Related]

  • 18. Cediranib in ovarian cancer: state of the art and future perspectives.
    Ruscito I, Gasparri ML, Marchetti C, De Medici C, Bracchi C, Palaia I, Imboden S, Mueller MD, Papadia A, Muzii L, Panici PB.
    Tumour Biol; 2016 Mar 29; 37(3):2833-9. PubMed ID: 26753963
    [Abstract] [Full Text] [Related]

  • 19. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
    Schmoll HJ, Cunningham D, Sobrero A, Karapetis CS, Rougier P, Koski SL, Kocakova I, Bondarenko I, Bodoky G, Mainwaring P, Salazar R, Barker P, Mookerjee B, Robertson J, Van Cutsem E.
    J Clin Oncol; 2012 Oct 10; 30(29):3588-95. PubMed ID: 22965961
    [Abstract] [Full Text] [Related]

  • 20. Safety evaluation of olaparib for treating ovarian cancer.
    Lheureux S, Bowering V, Karakasis K, Oza AM.
    Expert Opin Drug Saf; 2015 Aug 10; 14(8):1305-16. PubMed ID: 26051946
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.